ArticleFrontiers in cellular and infection microbiology2025
The impact of bronchoalveolar lavage fluid metagenomics next-generation sequencing on the diagnosis and management of patients with suspected pulmonary infection.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The future of fungal diagnostics: What's next in laboratory testing for invasive fungal infection?Medical mycology · 2026Review
- Metabolomics and Artificial Intelligence (AI) assisted metabolomics in the diagnosis of non-tuberculous mycobacterial infections: progress and challenges.New microbes and new infections · 2026Review
- Metagenomic next-generation sequencing for the diagnosis and evaluation of pediatric pleural effusion: a case series.BMC pulmonary medicine · 2026Article
- Case Report: A rare case of Pneumocystis jirovecii infection with left hydropneumothorax following immunotherapy for stage IVB clear cell renal cell carcinoma.Frontiers in medicine · 2026Article
- Metagenomic next-generation sequencing: new horizons in microbiology.Frontiers in cellular and infection microbiology · 2026Review
- Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to enhance the comprehension of the practical utility of bronchoalveolar lavage fluid (BALF) metagenomic next-generation sequencing (mNGS) in the clinical management of patients with suspected pneumonia. Methods: We retrospectively analyzed 296 individuals who underwent BALF mNGS and conventional microbial tests (CMTs) for suspected pneumonia. We compared the clinical characteristics between patients with pulmonary infection (PI) and those without pulmonary infection (NPI). The detection rate of mNGS and CMTs in different groups of patients were compared. The Sankey diagram was used to present the results of the influence of mNGS on diagnosis and treatment. Results: Comparison between PI and NPI showed that individuals with fever, concurrent malignant tumors, consolidation or ground-glass opacity on chest CT(Computed tomography) images, and elevated inflammatory markers on blood tests were more likely to develop lung infections. Analysis of the rate of positive detection between CMTs and mNGS in various subgroups revealed that mNGS had a significantly higher positive detection rate in patients with pulmonary infections (87.95% vs. 71.06%, p<0.001), in immunocompetent patients (86.91% vs. 68.08%, p<0.001), and in patients with malignant tumors (92.31% vs. 69.23%, p=0.035). Furthermore, mNGS helped initiate appropriate antibiotic treatment and confirmed the effectiveness of empirical treatment. Compared to immunocompetent patients, BALF mNGS in immunocompromised individuals with suspected lung infections yielded higher rates of accurate diagnosis (62.86% vs. 42.79%, p = 0.027) and more effective treatment (71.43% vs. 58.56%, p = 0.148). Conclusions: BALF mNGS identified a greater variety of pathogens than CMTs. Immunocompromised patients with suspected pneumonia may benefit more from BALF mNGS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.